NCT01100619View on ClinicalTrials.gov

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2012

Conditions
Papillary Thyroid CancerFollicular Thyroid CancerHuerthle Cell Thyroid CancerRenal Cell Carcinoma
Interventions
DRUG

rosiglitazone

one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later

DRUG

XL184

dosed with capsules daily

Trial Locations (5)

10466

Montefiore Medical Center, The Bronx

19104

Hospital of the University of Pennsylvania, Philadelphia

77230

The University of Texas M.D. Anderson Cancer Center, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Exelixis
All Listed Sponsors
lead

Exelixis

INDUSTRY